anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a perfume composition reproducing a fragrance of Chrysanthemum zawadskii Herb. ssp. coreanum (nakai) Y. Lee. The perfume composition has remarkable user preference by comprising cis-3-hexanol in -thujone, chrysanthenone, -thujone, -pinene, benzaldehyde, and the like, which are analyzed as fragrance components of Chrysanthemum zawadskii Herb. ssp. coreanum (nakai) Y. Lee through an SPME method.
PROBLEM TO BE SOLVED: To obtain the subject compound soluble in an aqueous medium, stable for a long period of time, stable to loss of fat decomposing activity under action of water, suitable as an aqueous solution to continuously flow into a mammalian gastrointestinal region. SOLUTION: A complex lipid uses an anion salt of the formula (R<1> and R<2> are each 10-25C alkanoyol, etc.; R<3> is H, carboxyl, etc.; R<4> is H or 10-25C hydrocarbon chain; A is O or NH) as a stabilizing additive for a digestive enzyme containing a lipase, etc. For example, a vegetable lecithin of a natural plant such as soybean is preferably and a complex lipid as a mixture of various lipids is suitably. In producing and processing a medicine preparation, the complex lipid is added, deactivation of lipase is prevented, lipid decomposition activity during a process is advantageously stabilized, a complex fat depends on a pH value in the production and the pH value is usually 3.5-9.0, preferably 4.0-7.0, especially preferably 5.0-6.5.
Growing research has highlighted that the consumption of dairy products improves the metabolic health in obese individuals by functioning as regulatory modulators. However, the molecular basis of this effect remains largely unknown. Herein, we report a dairy-derived peptide, which we named Miltin, that activates the thermogenesis of brown adipocytes and increases white adipocyte browning. Previously, Miltin was merely identified for its antioxidant capacity, although it is commonly present in different dairy products. In this study, we revealed the effect of Miltin in modulating adipose thermogenesis and further explored its potential in treating obesity through in vivo and in vitro strategies. The administration of Miltin in mice fed with a high-fat diet resulted in enhanced thermogenesis, improved glucose homeostasis, and reduced body mass and lipid accumulation, indicating the anti-obesity effect of Miltin. Genomic analysis revealed that Miltin modulates thermogenesis by inducing the activation of the MAPK signaling pathway by preferentially interacting with GADD45γ to promote its stability. Together, our findings indicate that Miltin's role in initiating the thermogenesis of adipocytes makes it a potential anti-obesity therapy for future development.
PROBLEM TO BE SOLVED: To obtain the subject composition capable of improving hair-dyeing strength and the persistence thereof, and further capable of imparting a conditioning effect to the hair by including a cationic direct hair dye, a cationic plant protein hydrolyzate, etc. SOLUTION: The subject hair dye composition contains (A) one or more kinds of cationic direct hair dyes (e.g. basic red 2) and (B) one or more kinds of cationic plant protein hydrolyzates (e.g. a wheat hydrolyzate) and/or a compound of the formula (R is an 8-20C alkyl or alkenyl; X<-> is an anion), in an proportion of 0.0001-2.5 wt.% component A and 0.1-10 wt.% component B based on the whole composition. A cationic, amphoteric and/or nonionic surfactant in an amount of 0.1-15 wt.% based on the whole composition is preferably included therein and the pH is preferably regulated so as to be 3.5-7. The composition is prepared as an aqueous composition such as an emulsion composition, a solid such as a gel, an aerosol foam or the like.
Inject 150 U of HYLENEX recombinant prior to start of subcutaneous fluid administration to facilitate absorption of up to 1,000 mL or more of solution. As with all parenteral fluid therapy, observe effect closely, with the same precautions for restoring fluid and electrolyte balance as in intravenous injections. The dose, the rate of injection, and the type of solution (saline, glucose, Ringer's, etc.) must be adjusted carefully to the individual patient. When solutions devoid of inorganic electrolytes are administered subcutaneously, hypovolemia may occur. This may be prevented by using solutions containing adequate amounts of inorganic electrolytes and/or controlling the volume and speed of administration.

HYLENEX recombinant may be added to small volumes of solution, such as fluid replacement solutions or solutions of drugs for subcutaneous injection. Subcutaneous fluids should be administered as directed by a physician. The dosage of subcutaneous fluids administered is dependent upon the age, weight, and clinical condition of the patient as well as laboratory determinations. The rate and volume of subcutaneous fluid administration should not exceed those employed for intravenous infusion. For premature infants or during the neonatal period, the daily dosage should not exceed 25 mL/kg and the rate of administration should not be greater than 2 mL per minute.
Children identified at risk for the development of autism spectrum disorder (ASD) by scoring a 3 or higher on the MCHAT-R. Participants should not have a history of extreme pre-term birth or underlying neurological disorders such as seizures or cerebral palsy.
The disruptor of telomeric silencing 1-like (DOT1L), a specific histone methyltransferase that catalyzed methylation of histone H3 on lysine 79, was associated with the pathogenesis of many diseases, but its role in peritoneal fibrosis remained unexplored. Here, we examined the role of DOT1L in the expression and activation of protein tyrosine kinases and development of peritoneal fibrosis. We found that a significant rise of DOT1L expression in the fibrotic peritoneum tissues from long-term PD patients and mice. Inhibition of DOT1L significantly attenuated the profibrotic phenotypic differentiation of mesothelial cells and macrophages, and alleviated peritoneal fibrosis. Mechanistically, RNA sequencing and proteomic analysis indicated that DOT1L was mainly involved in the processes of protein tyrosine kinase binding and extracellular matrix structural constituent in the peritoneum. Chromatin immunoprecipitation (ChIP) showed that intranuclear DOT1L guided H3K79me2 to upregulate EGFR in mesothelial cells and JAK3 in macrophages. Immunoprecipitation and immunofluorescence showed that extranuclear DOT1L could interact with EGFR and JAK3, and maintain the activated signaling pathways. In summary, DOT1L promoted the expression and activation of tyrosine kinases (EGFR in mesothelial cells and JAK3 in macrophages), promoting cells differentiate into profibrotic phenotype and thus peritoneal fibrosis. We provide the novel mechanism of dialysis-related peritoneal fibrosis (PF) and the new targets for clinical drug development. DOT1L inhibitor had the PF therapeutic potential.
The present invention discloses an efficient extraction and separation process of antioxidant mushroom polysaccharide. The process includes the steps of straw mushroom pretreatment, crushing, enzymatic extraction and enzyme inactivation, centrifugation, ultrafiltration separation, concentration and drying. Polysaccharide extraction by cellulase and multiple ultrafiltration are employed to obtain a polysaccharide obtained sample liquid. The enzymatic extraction process designed by the invention has high efficiency, and the mushroom polysaccharide has strong antioxidant activity. The yield of straw mushroom polysaccharide extraction by cellulase is 21.38%, which is 15.00% higher than the hot water extraction of polysaccharide. The ultrafiltration membrane separation process of straw mushroom polysaccharide designed by the present invention has the advantages of small equipment investment, simple process route and easiness to operate, and is applicable to mass production.
Trial emulations in observational data analyses can complement findings from randomized clinical trials, inform future trial designs, or generate evidence when randomized studies are not feasible due to resource constraints and ethical or practical limitations. Importantly, trial emulation designs facilitate causal inference in observational data analyses by enhancing counterfactual thinking and comparisons of real-world observations (e.g. Mendelian Randomization) to hypothetical interventions. In order to enhance credibility, trial emulations would benefit from prospective registration, publication of statistical analysis plans, and subsequent prospective benchmarking to randomized clinical trials prior to their publication. Confounding by indication, however, is the key challenge to interpreting observed intended effects of an intervention as causal in observational data analyses. We discuss the target trial emulation of the REDUCE-AMI randomized clinical trial (ClinicalTrials.gov ID NCT03278509; beta-blocker use in patients with preserved left ventricular ejection fraction after myocardial infarction) to illustrate the challenges and uncertainties of studying intended effects of interventions without randomization to account for confounding. We furthermore directly compare the findings, statistical power, and clinical interpretation of the results of the REDUCE-AMI target trial emulation to those from the simultaneously published randomized clinical trial. The complexity and subtlety of confounding by indication when studying intended effects of interventions can generally only be addressed by randomization.
The literature includes studies that investigate the relationship of pneumoperitoneum and different positions with intracranial pressure during laparoscopy. Reverse Trendelenburg position has been shown to slightly reduce the intracranial pressure associated with pneumoperitoneum. However, there are no studies on the effect of the timing of reverse Trendelenburg position on intracranial pressure. This study will monitor the effect of reverse Trendelenburg position before or after pneumoperitoneum on intracranial pressure and regional cerebral oxygen saturation. Ultrasound guided measurement of the optic nerve sheath diameter as a non-invasive method will be used for measurement. The investigators believe reverse Trendelenburg position before pneumoperitoneum may prevent undesired sudden increases in intracranial pressure.
The present invention relates to novel VEGF protein products, and nucleic acids encoding these novel protein products, comprising exons 1-6 and 8 of the VEGF gene, and derivatives thereof, and these uses in treating the cardiovascular system and its diseases through effects on anatomy, conduit function, and permeability. VEGF145 and its derivatives have been found to be active mitogens for vascular endothelial cells and to function as angiogenic factors in-vivo. VEGF145 and its derivatives have novel properties compared with previously characterized VEGF species with respect to cellular distribution, susceptibility to oxidative damage, and extra-cellular matrix (ECM) binding ability. The present invention also relates to derivatives of VEGF145 which have altered properties in that they have altered biological activity and altered heparin-binding activity when compared to VEGF145. The present invention provides methods of treating the cardiovascular system, enhancing endothelialization of diseased vessels, and enhancing drug permeation by providing the novel VEGF protein products. The invention also provides expression vectors, compositions, and kits for use in the methods of the invention.
Egypt is considered one of the countries with large liver disease burden in the world being endemic with bilharziasis and hepatitis C for decades. Limitations in health care resource further augment the magnitude of the problem allowing the development of disease specific complications in absence of effective treatments over the past. With discovery of anti-schistosomal therapy and implementation of the national program for eliminating bilharziasis; bilharzial liver disease incidence regressed markedly. However; complications of bilharzial liver disease are still present. The situation has been repeated with hepatitis C which is still a major health problem in Egypt regardless of the availability of highly effective interferon free antiviral regimens. This is mainly due to the large number of infected patients (estimated to be more than 6 million) \[1\], re-infection and presence of complications that needs further management. The need for addressing these major health problems in Egypt provoked a lot of research in the field of hepatology. Egyptian and non-Egyptian researchers have published a lot of scientific reports about liver diseases in Egypt. Since the ancient age of the pharaohs there were written evidence about liver disease in Egypt. It was reported in the Ebres Papyrus (around 2600 BC) that hardness of the liver occurs secondary to excess alcohol ingestion \[2\]. This was one of the oldest documented detailed medical literatures in the history of mankind. In the recent age there were a lot reports from Egypt about bilharziasis and other parasitic infestations as the one published by Cobbold in 1982 about injurious parasites in Egypt \[3\]. Further enormous amount of publications has been released afterwards. Reviewing this evidence and creating an indexed data base for it could be of value for the national and international hepatology platforms. I aim with other colleagues at reviewing all published evidence in the field of hepatology from Egypt up to January 2016 and classifying it by different key words to build a data base of liver disease evidence in Egypt. This data base will be continuously updated by published data after January 1st 2016 and will be the reference for researchers from Egypt and rest of the world. The data base will invite all authors from Egypt to provide their raw data of published articles to be available for further analyses by other researchers. Moreover the data base work team will start a series of systematic reviews and meta analyses for the available relevant data aiming at addressing the areas of strength and areas of weakness in liver disease research in Egypt making further recommendations to the research authorities about what is missing and how it is better to be addressed in their future research calls. This pilot research work can be reproduced elsewhere by other researchers in their own countries making use of their published data and advising their local research authorities to fill up the gaps in liver research in their own countries. Hopefully in the near future we will have these groups working together in a network driving liver research globally.
Terminalia ferdinandiana (T. ferdinandiana) leaf extract can be provided in a composition for use in inhibiting bacterial growth. The extract or composition can be in or as a personal hygiene product e.g. a deodorant or anti-perspirant, a cosmetic, a cosmeceutical, a surface treatment product or a preservative, and can include T. ferdinandiana fruit extract. The leaf extract can be a methanolic extract, alcoholic extract, steam extract, aqueous extract; ethyl acetate extract; chloroform extract; or hexane extract, and can include a tannin e.g. chebulic acid, corilagen, chebulinic acid or chebulagic acid and/or at least one flavone e.g. luteolin. The composition can be provided as a topical skin application.
Molecules comprising aminooxy groups are provided, wherein the aminooxy groups provide attachment sites for the covalent attachment of other molecules. In one embodiment, polyoxyethylene molecules comprising aminooxy groups are provided that can be conjugated to wide variety of biologically active molecules including poly(amino acids). In another embodiment, valency platform molecules comprising aminooxy groups are provided. The aminooxy groups can be used to form covalent bonds with biological molecules such as poly(amino acids). The aminooxy groups can, for example, react with poly(amino acids) modified to contain carbonyl groups, such as glyoxyl groups, to form a conjugate of the valency platform molecule and the biologically active molecule via an oxime bond. The valency platform molecules comprising aminooxy groups are advantageously reactive in the formation of conjugates, and they also can be readily synthesized to form a composition with very low polydispersity.
The present invention relates to a container for an analyte-sensitive gel. When analyte contacts such a gel it causes a gel-sol transition resulting in decreased viscosity of the gel. Such gels can be used for controlling the rate of release of an agent from a reservoir in response to the concentration of an analyte. The container is configured to allow analyte to pass into the container and contact the gel and to allow agent to diffuse out of the container. Such a container may be implantable in the body of a subject and therefore it is preferred if the container is constructed from materials that can be tolerated by the body for a period of time. Advantageously, the container limits the swelling and dilution of gel contained within the container caused by the influx of water into the gel by osmosis. The container therefore maintains the gel in a desired conformation and ensures a predictable release profile of the agent.
OBJECTIVE: Potential coeliac disease (PCD) is characterised by positive serological and genetic markers of coeliac disease with architecturally preserved duodenal mucosa. The clinical outcomes and rates of progression to overt coeliac disease in patients with PCD remain uncertain. In this systematic review and meta-analysis, we aimed to evaluate the clinical outcomes of patients with PCD.
DESIGN: We searched Medline, Embase, Scopus and Cochrane Library from 1991 through May 2024 to identify studies evaluating the clinical outcomes of patients with PCD. The progression rates to villous atrophy, seroconversion and response to a gluten-free diet (GFD) were analysed. A random-effect meta-analysis was performed, and the results were reported as pooled proportions with 95% CIs.
RESULTS: Seventeen studies comprising 1010 patients with PCD were included in the final analyses. The pooled prevalence of PCD among patients with suspected coeliac disease was 16% (95% CI 10% to 22%). The duration of follow-up in most of the studies was at least 1 year, with follow-up periods within individual studies ranging from 5 months to 13 years. During follow-up, 33% (95% CI 18% to 48%; I2=96.4%) of patients with PCD on a gluten-containing diet developed villous atrophy, and 33% (95% CI 17% to 48%; I2=93.0%) had normalisation of serology. Among those who adhered to a GFD, 88% (95% CI 79% to 97%; I2=93.2%) reported symptomatic improvement.
CONCLUSION: Almost a third of patients with PCD develop villous atrophy over time, whereas a similar proportion experience normalisation of serology despite a gluten-containing diet. Most symptomatic patients benefit from a GFD. These findings highlight the importance of structured follow-up and individualised management for patients with PCD.
Selective serotonin reuptake inhibitors (SSRIs), including fluoxetine, can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, buspirone, amphetamines, and St. John’s Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see Contraindications (4), Drug Interactions (7.1)]. Serotonin syndrome can also occur when these drugs are used alone. Serotonin syndrome signs and symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).

  
The concomitant use of fluoxetine with MAOIs is contraindicated. In addition, do not initiate fluoxetine in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection). If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking fluoxetine, discontinue fluoxetine before initiating treatment with the MAOI [see Contraindications (4) and Drug Interactions (7.1)].

  
Monitor all patients taking fluoxetine for the emergence of serotonin syndrome. Discontinue treatment with fluoxetine and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of fluoxetine with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.
Primary Objective: I. To determine the proportion of patients reaching a stem cell yield of 3 million CD34 cells/kg by second day of apheresis with intravenously administered AMD3100 among patients receiving primary therapy for myeloma with lenalidomide. Secondary Objectives: I. Safety and tolerability of intravenously administered AMD3100. II. Rate of failure to mobilize. Outline: Patients receive plerixafor IV on days 5-8 and filgrastim subcutaneously on days 1-8 in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.
FIELD: medicine, virology, pharmacology, chemotherapy. SUBSTANCE: invention proposes method of prophylaxis as decrease of development or reactivation of latent infection caused by herpes virus. Method involves administration of compound of the formula (A)   or the formula (B)  . Invention provides to perform prophylaxis in 18 h and up to 4 days after infection. EFFECT: enhanced effectiveness of treatment and prophylaxis. 4 cl, 3 tbl
BACKGROUND: Stroke represents a significant health crisis in the United States, claiming approximately 140,000 lives annually and ranking as the fifth leading cause of death.
OBJECTIVE: Utilizing data from the National Health and Nutrition Examination Survey (NHANES) for 2005 to 2008, this study examines the correlation between various sleep characteristics and both stroke morbidity and all-cause mortality among U.S. adults.
METHODS: We applied logistic regression, Cox regression, and subgroup analyses to a sample of 7,827 adults aged 18 and older from NHANES 2005-2008. The study focused on six sleep characteristics: duration of sleep, sleep onset latency, snoring frequency, number of awakenings, frequency of leg spasms during sleep, and daytime sleepiness, analyzing their impacts on stroke incidence and mortality rates.
RESULTS: Participants had an average age of 45.80 ± 0.45 years, with females accounting for 48.13 % of the sample. Analysis revealed significant associations between sleep duration, onset latency, number of awakenings, leg spasms, and daytime sleepiness with stroke incidence. However, these associations weakened with increasing confounders. Additionally, stroke patients showed a higher likelihood of using sleep aids. The influence of sleep disturbances on stroke appeared more pronounced in females and younger demographics. An association was also noted between the number of awakenings, sleep duration, and stroke mortality rates CONCLUSIONS: The study reinforces the critical role of maintaining healthy sleep patterns in preventing strokes and enhancing stroke prognosis, emphasizing specific sleep disturbances as potential risk factors.
Participants will increase dosage to 3 tablets per day at 4 weeks from the start of study participation. Participants will continue to take 3 tablets for 2 addiitonal weeks before increasing dose. If participants experience adverse side effects, participants will decrease dosage to 2 tablets.